US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

8.83

-0.3200-3.50%

Post-market: 8.830.00000.00%19:30 EDT

Volume:495.36K

Turnover:4.40M

Market Cap:490.73M

PE:-1.75

High:9.42

Open:9.15

Low:8.70

Close:9.15

52wk High:40.43

52wk Low:8.70

Shares:55.58M

Float Shares:19.23M

Volume Ratio:1.36

T/O Rate:2.58%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0580

EPS(LYR):-18.5643

ROE:-111.55%

ROA:-67.11%

PB:1.41

PE(LYR):-0.48

Loading ...

Overview Company News Filings

Maplight Therapeutics Inc - 330/6 Mg Once-Daily (Qd) Dose Did not Achieve Statistical Significance on Primary Endpoint

THOMSON REUTERS

Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia

THOMSON REUTERS

Maplight Therapeutics - Ml-007C-Ma Well Tolerated with no Serious or Drug-Related Severe Adverse Events

THOMSON REUTERS

Maplight Therapeutics - 210/3 Mg Bid Dose Shows Significant Panss Improvement at Week 5 in Phase 2 Trial

THOMSON REUTERS

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus

Simply Wall St.

MapLight Therapeutics price target raised to $43 from $35 at Canaccord

U.S. Research Roundup-deckers Brands, Rollins, United Rentals

Sector Update: Healthcare

MT Newswires Live

MapLight Therapeutics Seen Having Upside in Schizophrenia Trial Readout, UBS Says

MT Newswires Live

UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating

MT Newswires Live

MapLight Therapeutics price target raised to $52 from $48 at UBS

MapLight Therapeutics initiated with an Outperform at BMO Capital

Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer Disposes of USD 1.34 Million in Common Shares

Maplight Therapeutics CMO Erin Pennock Foff Sells USD 1.99 Million in Common Shares

Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout

Maplight Therapeutics Director Martin Babler Files Initial Beneficial Ownership Statement

Raymond James Initiates Coverage on MapLight Therapeutics With Strong Buy Rating

MT Newswires Live

Maplight Therapeutics Inc : Raymond James Initiates Coverage with Strong Buy Rating; Target Price $46

THOMSON REUTERS

Maplight Therapeutics Initiated at Strong Buy by Raymond James

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/MPLT/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MPLT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":8.83,"timestamp":1791576000000,"preClose":9.15,"halted":0,"volume":495355,"hourTrading":{"tag":"盘后","latestPrice":8.83,"preClose":8.83,"latestTime":"19:30 EDT","volume":2389,"amount":21106.17,"timestamp":1791588606185,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03497267759562844,"floatShares":19234500,"shares":55575700,"eps":-5.058,"marketStatus":"Market Closed","change":-0.32,"latestTime":"10-09 16:00:00 EDT","open":9.15,"high":9.415,"low":8.7,"amount":4396009.619365,"amplitude":0.078142,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.058,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":9.15,"preHourTrading":{"tag":"盘前","latestPrice":9.69,"preClose":9.15,"latestTime":"08:59 EDT","volume":66,"amount":613.670046,"timestamp":1791550796981,"change":0.54,"changeRate":0.059016,"amplitude":0.057923},"postHourTrading":{"tag":"盘后","latestPrice":8.83,"preClose":8.83,"latestTime":"19:30 EDT","volume":2389,"amount":21106.17,"timestamp":1791588606185,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3636488768783048,"impliedVol":0.9887,"impliedVolPercentile":0.3333},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","floatShares":19234500,"roa":"-67.11%","roe":"-111.55%","lyrEps":-18.564313,"volumeRatio":1.3636488768783048,"shares":55575700,"dividePrice":0,"high":9.415,"amplitude":0.078142,"preClose":9.15,"low":8.7,"week52Low":8.7,"pbRate":"1.41","week52High":40.43,"institutionHeld":0,"latestPrice":8.83,"eps":-5.058,"divideRate":0,"volume":495355,"delay":0,"ttmEps":-5.058,"open":9.15,"prevYearClose":17.565,"prevWeekClose":9.82,"prevMonthClose":10.19,"prevQuarterClose":10.19,"fiveDayClose":9.82,"twentyDayClose":13,"sixtyDayClose":37.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MPLT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"MPLT","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-05-14","symbol":"MPLT","fiscalQuarterEnding":"2026/03","expectedEps":-0.91,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-1.34},{"market":"US","date":"2026-03-26","symbol":"MPLT","fiscalQuarterEnding":"2025/12","expectedEps":-1.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-2.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MPLT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MPLT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3571,"buy":0.5,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MPLT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MPLT","date":"2026-10-09","current":-1.745749,"percent":1,"low":-9.047313,"twenty":-8.011778,"median":-7.261334,"eighty":-3.2766,"high":-2.212611,"avg":-6.406557,"sd":2.079588,"marketCap":508517828},"quantilePoints":[{"date":"2025-10-31","current":-8.673514,"twenty":-8.310978,"median":-7.61973,"eighty":-7.489746,"marketCap":801692922},{"date":"2025-11-07","current":-7.620605,"twenty":-8.035178,"median":-7.644213,"eighty":-7.545137,"marketCap":704372551},{"date":"2025-11-14","current":-6.742394,"twenty":-7.98511,"median":-7.554503,"eighty":-7.23627,"marketCap":623199506},{"date":"2025-11-21","current":-6.274959,"twenty":-7.73109,"median":-7.394197,"eighty":-6.810384,"marketCap":579994498},{"date":"2025-11-28","current":-6.435493,"twenty":-7.639491,"median":-7.190943,"eighty":-6.54881,"marketCap":594832581},{"date":"2025-12-05","current":-7.783335,"twenty":-7.714027,"median":-7.115398,"eighty":-6.435493,"marketCap":800383679},{"date":"2025-12-12","current":-8.528142,"twenty":-7.986054,"median":-7.394197,"eighty":-6.45249,"marketCap":876974375},{"date":"2025-12-19","current":-8.462361,"twenty":-8.266224,"median":-7.554503,"eighty":-6.54881,"marketCap":870209954},{"date":"2025-12-26","current":-7.689969,"twenty":-8.289163,"median":-7.620605,"eighty":-6.624355,"marketCap":790782566},{"date":"2026-01-02","current":-7.454432,"twenty":-8.20424,"median":-7.61973,"eighty":-6.670627,"marketCap":766561577},{"date":"2026-01-09","current":-7.295285,"twenty":-8.111814,"median":-7.53948,"eighty":-6.75706,"marketCap":750196044},{"date":"2026-01-16","current":-7.84275,"twenty":-8.074467,"median":-7.609335,"eighty":-6.818055,"marketCap":806493478},{"date":"2026-01-23","current":-7.885189,"twenty":-7.999774,"median":-7.554503,"eighty":-6.827382,"marketCap":810857620},{"date":"2026-01-30","current":-7.885189,"twenty":-8.004018,"median":-7.620167,"eighty":-6.893484,"marketCap":810857620},{"date":"2026-02-06","current":-6.662942,"twenty":-7.999774,"median":-7.609335,"eighty":-6.893484,"marketCap":685170325},{"date":"2026-02-13","current":-7.308017,"twenty":-7.988887,"median":-7.547968,"eighty":-7.020967,"marketCap":751505286},{"date":"2026-02-20","current":-7.605091,"twenty":-7.988887,"median":-7.532944,"eighty":-7.096512,"marketCap":782054282},{"date":"2026-02-27","current":-7.392895,"twenty":-7.98511,"median":-7.541432,"eighty":-7.116712,"marketCap":760233571},{"date":"2026-03-06","current":-7.622066,"twenty":-7.966096,"median":-7.547968,"eighty":-7.127226,"marketCap":783799939},{"date":"2026-03-13","current":-8.122848,"twenty":-7.991064,"median":-7.592359,"eighty":-7.180699,"marketCap":835296817},{"date":"2026-03-20","current":-7.422602,"twenty":-8.000623,"median":-7.590237,"eighty":-7.203617,"marketCap":763288470},{"date":"2026-03-27","current":-5.207658,"twenty":-7.991064,"median":-7.583871,"eighty":-7.203617,"marketCap":839224545},{"date":"2026-04-02","current":-5.640953,"twenty":-7.988887,"median":-7.541432,"eighty":-7.116384,"marketCap":909050820},{"date":"2026-04-10","current":-7.964495,"twenty":-7.986054,"median":-7.516065,"eighty":-6.867043,"marketCap":1283494221},{"date":"2026-04-17","current":-7.720766,"twenty":-7.972363,"median":-7.507481,"eighty":-6.969974,"marketCap":1244216941},{"date":"2026-04-24","current":-7.883252,"twenty":-7.986054,"median":-7.516065,"eighty":-7.077626,"marketCap":1270401794},{"date":"2026-05-01","current":-8.966125,"twenty":-8.009111,"median":-7.554503,"eighty":-7.116384,"marketCap":1444908993},{"date":"2026-05-08","current":-8.214962,"twenty":-8.052399,"median":-7.590237,"eighty":-7.121808,"marketCap":1323857628},{"date":"2026-05-15","current":-6.658186,"twenty":-8.072823,"median":-7.605091,"eighty":-7.121808,"marketCap":1328174850},{"date":"2026-05-22","current":-6.655912,"twenty":-8.056678,"median":-7.585993,"eighty":-6.867043,"marketCap":1327721393},{"date":"2026-05-29","current":-6.769572,"twenty":-8.053247,"median":-7.547968,"eighty":-6.753265,"marketCap":1350394231},{"date":"2026-06-05","current":-6.842314,"twenty":-8.050011,"median":-7.507675,"eighty":-6.705014,"marketCap":1364904847},{"date":"2026-06-12","current":-6.899144,"twenty":-8.036085,"median":-7.484139,"eighty":-6.662816,"marketCap":1376241266},{"date":"2026-06-18","current":-6.64,"twenty":-8.014204,"median":-7.474515,"eighty":-6.654094,"marketCap":1324547195},{"date":"2026-06-26","current":-7.265128,"twenty":-8.003169,"median":-7.454432,"eighty":-6.652876,"marketCap":1449247804},{"date":"2026-07-02","current":-8.201684,"twenty":-8.01675,"median":-7.469285,"eighty":-6.653639,"marketCap":1636071990},{"date":"2026-07-10","current":-9.047313,"twenty":-8.054945,"median":-7.484139,"eighty":-6.655912,"marketCap":1804757904},{"date":"2026-07-17","current":-8.460828,"twenty":-8.122848,"median":-7.507675,"eighty":-6.658186,"marketCap":1687766060},{"date":"2026-07-24","current":-8.008463,"twenty":-8.137812,"median":-7.547968,"eighty":-6.662732,"marketCap":1597528165},{"date":"2026-07-31","current":-3.189291,"twenty":-8.129236,"median":-7.516065,"eighty":-6.653448,"marketCap":636199834},{"date":"2026-08-07","current":-3.018802,"twenty":-8.123697,"median":-7.486261,"eighty":-6.561799,"marketCap":602190577},{"date":"2026-08-14","current":-2.692276,"twenty":-8.099082,"median":-7.474515,"eighty":-6.526795,"marketCap":537055294},{"date":"2026-08-21","current":-2.266153,"twenty":-8.09314,"median":-7.454432,"eighty":-6.435493,"marketCap":520823053},{"date":"2026-08-28","current":-3.032366,"twenty":-8.06605,"median":-7.420317,"eighty":-6.349031,"marketCap":696919516},{"date":"2026-09-04","current":-3.177455,"twenty":-8.055812,"median":-7.370362,"eighty":-6.26295,"marketCap":730264947},{"date":"2026-09-11","current":-3.333426,"twenty":-8.052399,"median":-7.329236,"eighty":-6.1487,"marketCap":766111286},{"date":"2026-09-18","current":-2.737351,"twenty":-8.049665,"median":-7.312639,"eighty":-6.03858,"marketCap":629117139},{"date":"2026-09-25","current":-2.601934,"twenty":-8.035579,"median":-7.308017,"eighty":-5.386392,"marketCap":597994736},{"date":"2026-10-02","current":-2.328683,"twenty":-8.020709,"median":-7.275626,"eighty":-3.397933,"marketCap":535194173},{"date":"2026-10-09","current":-2.212611,"twenty":-8.011778,"median":-7.261334,"eighty":-3.2766,"marketCap":508517828}],"updateTime":1791639253465},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MPLT\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654142010","title":"Maplight Therapeutics Inc - 330/6 Mg Once-Daily (Qd) Dose Did not Achieve Statistical Significance on Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2654142010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654142010?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014822","title":"Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014822","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014822?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014373","title":"Maplight Therapeutics - Ml-007C-Ma Well Tolerated with no Serious or Drug-Related Severe Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014373?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654014340","title":"Maplight Therapeutics - 210/3 Mg Bid Dose Shows Significant Panss Improvement at Week 5 in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654014340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654014340?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA6GMRCS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654601468","title":"MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2654601468","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654601468?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":"The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to place","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333379/0/en/MapLight-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-ZEPHYR-Trial-of-ML-007C-MA-in-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4527","MA","LU2168563687.JPY","LU0823421333.USD","FDFF","LU2092937148.SGD","LU0061475181.USD","VFH","LU0107464264.USD","LU1712237335.SGD","LU1983260115.SGD","LU1316542783.SGD","LU0642271901.SGD","LU2168564149.EUR","LU2077746001.SGD","LU1861217088.USD","LU0823421416.USD","FNCL","LU1280957306.USD","BK4139","LU0823417653.USD","IE000WAW04H5.SGD","UYG","LU0708995401.HKD","LU2092627202.USD","LU0056508442.USD","ASD","LU0823434583.USD","BK4533","LU0557290698.USD","LU1815333072.USD","MPLT","LU1868836914.USD","IPAY","LU1718418525.SGD","IE00BKDWB100.SGD","LU2420271590.USD","LU2506951958.HKD","SG9999003800.SGD","LU1732800096.USD","IYG","LU2360107671.USD","BK4585","STBQ","XLF","BID","LU0096362180.USD","LATR","IE00B4JS1V06.HKD","LU0210533765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654098633","title":"MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2654098633","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654098633?lang=en_us&edition=fundamental","pubTime":"2026-07-27 08:26","pubTimestamp":1785111993,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (MPLT) has drawn investor attention recently as its clinical-stage central nervous system pipeline, including candidates for schizophrenia, Alzheimer’s disease psychosis and Parkinson’s disease, trades around $36.56 with a market value near $1.66 billion.\nSee our latest analysis for MapLight Therapeutics.\nFor context, MapLight Therapeutics’ share price return has been strong over 2024, with a year to date gain of 118.01% and a 90 day share price return of 19.32%...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mplt/maplight-therapeutics/news/maplight-therapeutics-mplt-rally-puts-its-cns-story-and-valu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mplt/maplight-therapeutics/news/maplight-therapeutics-mplt-rally-puts-its-cns-story-and-valu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CNS","MPLT","BK4135","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653308984","title":"MapLight Therapeutics price target raised to $43 from $35 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2653308984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653308984?lang=en_us&edition=fundamental","pubTime":"2026-07-24 18:50","pubTimestamp":1784890228,"startTime":"0","endTime":"0","summary":"Canaccord analyst Sumant Kulkarni raised the firm’s price target on MapLight Therapeutics (MPLT) to $43 from $35 and keeps a Buy rating on the shar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-raised-to-43-from-35-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-raised-to-43-from-35-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653701014","title":"U.S. Research Roundup-deckers Brands, Rollins, United Rentals","url":"https://stock-news.laohu8.com/highlight/detail?id=2653701014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653701014?lang=en_us&edition=fundamental","pubTime":"2026-07-24 15:14","pubTimestamp":1784877253,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Deckers Brands, Rollins, United RentalsJuly 24 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Decker","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL4N43Q0HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","ACI","FCNCA","HON","BPOP","AMUU","ROL","LRCX","CHPS","MISL","INTC","MPLT","PNFP","ALK","CTSH","AMP","EMET","AMD","DOMO","LMT","MBWM","SETM","R","BX","PKG","AAL","NIC","NSC","MEDP","FOA","AMDS","LOB","KRMN","FCX","JUP.UK","TINY","DOV","DOW","AMAT","SAM","OBK","MOH","DECK","TEK","DFTX","NVR","GPZ","THRM","EW","CMCSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653200377","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2653200377","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653200377?lang=en_us&edition=fundamental","pubTime":"2026-07-22 03:16","pubTimestamp":1784661378,"startTime":"0","endTime":"0","summary":"Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF  adding 0.3%.The iShares Biotechnology ETF  climbed 1.3%.In corporate news, MapLight Therapeutics  is seen having meaningful upside in the upcoming ML-007 Ph2 schizophrenia trial readout, with the study completed on June 4th and data expected in mid-August, UBS said in a note. MapLight shares rose 3%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","BK4588","BK4137","LABU","BK4581","LU0128526141.USD","LU0029874061.USD","BK4585","MPLT","XLV","HCSG","XBI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653204876","title":"MapLight Therapeutics Seen Having Upside in Schizophrenia Trial Readout, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2653204876","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653204876?lang=en_us&edition=fundamental","pubTime":"2026-07-22 00:39","pubTimestamp":1784651989,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics  is seen having meaningful upside in the upcoming ML-007 Ph2 schizophrenia trial readout, with the study completed on June 4th and data expected in mid-August, UBS said in a note Tuesday.The bank said investors are primarily focused on whether ML-007 can demonstrate a clean tolerability profile, with low rates of vomiting and nausea that can differentiate it from Cobenfy.UBS said the potential advantages of once-daily dosing and no food restrictions are particularly important in the schizophrenia patient group given challenges with adherence and cognitive impairment, adding that better tolerability could be a win even with similar efficacy.UBS maintained a buy rating and raised price target to $52 from $48.Price: 37.00, Change: +1.01, Percent Change: +2.81","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653203312","title":"UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2653203312","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653203312?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:37","pubTimestamp":1784641040,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc. (MPLT) has an average rating of Buy and mean price target of $43.23, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653527435","title":"MapLight Therapeutics price target raised to $52 from $48 at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2653527435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653527435?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:11","pubTimestamp":1784632310,"startTime":"0","endTime":"0","summary":"UBS raised the firm’s price target on MapLight Therapeutics (MPLT) to $52 from $48 and keeps a Buy rating on the shares. The upcoming Phase 2 reado...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-raised-to-52-from-48-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-price-target-raised-to-52-from-48-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653468092","title":"MapLight Therapeutics initiated with an Outperform at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2653468092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653468092?lang=en_us&edition=fundamental","pubTime":"2026-07-21 04:30","pubTimestamp":1784579421,"startTime":"0","endTime":"0","summary":"BMO Capital initiated coverage of MapLight Therapeutics (MPLT) with an Outperform rating and $46 price target Published first on TheFly – the ultim...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-an-outperform-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-an-outperform-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652294732","title":"Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer Disposes of USD 1.34 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2652294732","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652294732?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:03","pubTimestamp":1784541805,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer disposes of USD 1.34 million in common sharesMapLight Therapeutics Chief Discovery Officer Anatol Kreitzer sold 36,284 shares of Voting Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDLbXNwwm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer Disposes of USD 1.34 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652236527","title":"Maplight Therapeutics CMO Erin Pennock Foff Sells USD 1.99 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2652236527","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652236527?lang=en_us&edition=fundamental","pubTime":"2026-07-18 09:44","pubTimestamp":1784339040,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics CMO Erin Pennock Foff sells USD 1.99 million in common sharesMaplight Therapeutics Chief Medical Officer Erin Pennock Foff reported sales totaling 57,303 shares on July 15-17.Sha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260718:nNDL49Yb9x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maplight Therapeutics CMO Erin Pennock Foff Sells USD 1.99 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648689162","title":"Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2648689162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648689162?lang=en_us&edition=fundamental","pubTime":"2026-07-02 23:15","pubTimestamp":1783005317,"startTime":"0","endTime":"0","summary":"Analyst Francois Brisebois of LifeSci Capital maintained a Buy rating on MapLight Therapeutics, Inc., retaining the price target of $45.00. Francoi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-maplight-therapeutics-reaffirms-45-price-target-ahead-of-key-phase-2-zephyr-readout-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-maplight-therapeutics-reaffirms-45-price-target-ahead-of-key-phase-2-zephyr-readout-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646890463","title":"Maplight Therapeutics Director Martin Babler Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2646890463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646890463?lang=en_us&edition=fundamental","pubTime":"2026-06-26 05:47","pubTimestamp":1782424064,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics director Martin Babler files initial beneficial ownership statementMapLight Therapeutics director Martin Babler filed an initial Form 3 statement dated June 23.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL3Ksnj9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646877598","title":"Raymond James Initiates Coverage on MapLight Therapeutics With Strong Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2646877598","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646877598?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:36","pubTimestamp":1782387416,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc. (MPLT) has an average rating of Buy and mean price target of $39.55, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MPLT","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646787219","title":"Maplight Therapeutics Inc : Raymond James Initiates Coverage with Strong Buy Rating; Target Price $46","url":"https://stock-news.laohu8.com/highlight/detail?id=2646787219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646787219?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:18","pubTimestamp":1782386337,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nFWN42X0I5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646879758","title":"Maplight Therapeutics Initiated at Strong Buy by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2646879758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646879758?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:05","pubTimestamp":1782381900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings(END) Dow Jones NewswiresJune 25, 2026 06:05 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","RJF","LU1804176565.USD","BK4127","BK4585","LU0971096721.USD","LU2265009873.SGD","MPLT","LENZ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","BK4588","BK4007","IE00B3QW5Z07.USD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":118,"code":"91000000","status":"200"}]}}